Cart
Account
Your Orders
Sign In
CRISPR Delivery Methods for Scalable Gene Editing
Gene editing programs move beyond proving CRISPR works to determining whether it can scale. Delivery strategy shapes everything from manufacturing complexity to cost and clinical feasibility, and while viral vectors like AAV remain standard, non-viral approaches such as protein and mRNA are emerging as flexible alternatives. With partners like Synthego providing high-quality CRISPR components, teams have more options than ever to align their delivery strategy with long-term program goals.
